vs
Side-by-side financial comparison of CALLAN JMB INC. (CJMB) and Korro Bio, Inc. (KRRO). Click either name above to swap in a different company.
Korro Bio, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.2M, roughly 1.1× CALLAN JMB INC.).
Korro Bio, Inc. is a clinical-stage biotechnology company focused on developing innovative RNA editing therapies for rare and severe genetic diseases. It leverages its proprietary oligonucleotide platform to target disease-causing mutations, with core pipelines covering ophthalmology, respiratory and neuromuscular disorder segments, striving to address unmet medical needs for global patients.
CJMB vs KRRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.3M |
| Net Profit | $-2.6M | — |
| Gross Margin | 30.3% | — |
| Operating Margin | -216.6% | — |
| Net Margin | -223.8% | — |
| Revenue YoY | — | -43.1% |
| Net Profit YoY | — | -136.1% |
| EPS (diluted) | $-0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $1.3M | ||
| Q3 25 | $1.4M | $1.1M | ||
| Q2 25 | $1.7M | $1.5M | ||
| Q1 25 | $1.4M | $2.5M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.7M | $-18.1M | ||
| Q2 25 | $-1.4M | $-25.8M | ||
| Q1 25 | $-1.2M | $-23.4M | ||
| Q3 24 | — | $-21.0M | ||
| Q2 24 | — | $-21.8M | ||
| Q1 24 | — | $-19.6M |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 38.6% | — | ||
| Q1 25 | 42.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -216.6% | — | ||
| Q3 25 | -129.9% | -1764.9% | ||
| Q2 25 | -84.2% | -1863.2% | ||
| Q1 25 | -85.4% | -981.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -223.8% | — | ||
| Q3 25 | -188.8% | -1657.0% | ||
| Q2 25 | -83.9% | -1765.1% | ||
| Q1 25 | -85.6% | -917.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.58 | — | ||
| Q3 25 | $-0.61 | $-1.92 | ||
| Q2 25 | $-0.31 | $-2.74 | ||
| Q1 25 | $-0.32 | $-2.49 | ||
| Q3 24 | — | $-2.26 | ||
| Q2 24 | — | $-2.43 | ||
| Q1 24 | — | $-2.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $75.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3M | $51.4M |
| Total Assets | $5.8M | $113.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $75.2M | ||
| Q3 25 | $2.8M | $92.5M | ||
| Q2 25 | $4.2M | $96.4M | ||
| Q1 25 | $5.2M | $115.0M | ||
| Q3 24 | — | $137.0M | ||
| Q2 24 | — | $157.4M | ||
| Q1 24 | — | $138.8M |
| Q4 25 | $2.3M | $51.4M | ||
| Q3 25 | $4.2M | $99.0M | ||
| Q2 25 | $5.8M | $115.1M | ||
| Q1 25 | $6.8M | $139.0M | ||
| Q3 24 | — | $179.6M | ||
| Q2 24 | — | $198.1M | ||
| Q1 24 | — | $151.4M |
| Q4 25 | $5.8M | $113.5M | ||
| Q3 25 | $7.7M | $161.6M | ||
| Q2 25 | $9.0M | $180.4M | ||
| Q1 25 | $8.5M | $202.2M | ||
| Q3 24 | — | $243.5M | ||
| Q2 24 | — | $249.6M | ||
| Q1 24 | — | $198.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-659.0K | $-78.6M |
| Free Cash FlowOCF − Capex | — | $-79.1M |
| FCF MarginFCF / Revenue | — | -6120.7% |
| Capex IntensityCapex / Revenue | 0.0% | 40.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-140.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-659.0K | $-78.6M | ||
| Q3 25 | $-1.8M | $-17.2M | ||
| Q2 25 | $-563.3K | $-19.2M | ||
| Q1 25 | $-1.6M | $-24.5M | ||
| Q3 24 | — | $-16.1M | ||
| Q2 24 | — | $-14.6M | ||
| Q1 24 | — | $-21.9M |
| Q4 25 | — | $-79.1M | ||
| Q3 25 | $-1.9M | $-17.4M | ||
| Q2 25 | $-995.8K | $-19.4M | ||
| Q1 25 | $-1.6M | $-24.6M | ||
| Q3 24 | — | $-21.0M | ||
| Q2 24 | — | $-20.6M | ||
| Q1 24 | — | $-27.5M |
| Q4 25 | — | -6120.7% | ||
| Q3 25 | -133.5% | -1592.1% | ||
| Q2 25 | -59.8% | -1326.6% | ||
| Q1 25 | -108.8% | -963.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 40.1% | ||
| Q3 25 | 11.7% | 16.1% | ||
| Q2 25 | 26.0% | 9.6% | ||
| Q1 25 | 1.0% | 4.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
KRRO
Segment breakdown not available.
